Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) ROCE % : -72.10% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ginkgo Bioworks Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ginkgo Bioworks Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -72.10%.

Ginkgo Bioworks Holdings ROCE % Historical Data

The historical data trend for Ginkgo Bioworks Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ginkgo Bioworks Holdings ROCE % Chart

Ginkgo Bioworks Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-20.34

-144.65

-98.61

-46.17

Ginkgo Bioworks Holdings Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial										-27.86	-37.59	-33.83	-38.16	-72.10

Ginkgo Bioworks Holdings ROCE % Calculation

Ginkgo Bioworks Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-892.847	/	( ( (2539.321 - 172.962)	+	(1665.342 - 163.86) )	/ 2 )
	=	-892.847	/	( (2366.359	+	1501.482)	/ 2 )
	=	-892.847	/	1933.9205
	=	-46.17 %

Ginkgo Bioworks Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-1211.072	/	( ( (2026.392 - 168.462)	+	(1665.342 - 163.86) )	/ 2 )
	=	-1211.072	/	( ( 1857.93	+	1501.482 )	/ 2 )
	=	-1211.072	/	1679.706
	=	-72.10 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Ginkgo Bioworks Holdings (NYSE:DNA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ginkgo Bioworks Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Ginkgo Bioworks Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ginkgo Bioworks Holdings (Ginkgo Bioworks Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ginkgo Bioworks Holdings Inc (NYSE:DNA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

DNA.WS:USA DNA:Mexico

Address

27 Drydock Avenue, 8th Floor, Boston, MA, USA, 02210

Website

https://www.ginkgobioworks.com

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Foundry and Biosecurity. The Biosecurity segment generates the majority of revenue.

Executives

Jason R Kelly	director, officer: CEO & Founder	667 MADISON AVENUE, C/O CORVEX MANAGEMENT LP, NEW YORK NY 10065
Mark E. Dmytruk	officer: Chief Financial Officer	C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Barry Canton	10 percent owner	C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Reshma P. Shetty	director, 10 percent owner, officer: President, COO & Founder	C/O SOARING EAGLE ACQUISITION CORP., 955 FIFTH AVENUE, NEW YORK NY 10075
Christian O Henry	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Harry Sloan	director, officer: CEO, Chairman	1450 2ND STREET, SUITE 247, SANTA MONICA CA 90401
Shyam Sankar	director	C/O PALANTIR TECHNOLOGIES INC., 1200 17TH STREET, FLOOR 15, DENVER CO 80202
Steven P. Coen	officer: Chief Accounting Officer	C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marie E. Fallon	officer: Chief Accounting Officer	C/O GINKGO BIOWORKS, INC., 27 DRYDOCK AVENUE, 8TH FLOOR, BOSTON MA 02210
Marijn E Dekkers	director	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210
Kathy Hopinkah Hannan	director	ANNALY CAPITAL MANAGEMENT, INC., 1211 AVE. OF THE AMERICAS, NEW YORK NY 10036
David C. Ott	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc	10 percent owner	55 RAILROAD AVENUE, GREENWICH CT 06830